A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Recruiting

Phase 3

IBI363 vs. DocetaxelA Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Sponsor:

Takeda

Code:

NCT07217301

Conditions

IO-resistant sqNSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TAK-928

Control Arm

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-29. This information was provided to ClinicalTrials.gov by Takeda on 2026-06-26.